Literature DB >> 15567101

Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

Daqing Wang1, Mary E Christopher, Les P Nagata, Monika A Zabielski, Hongduo Li, Jonathan P Wong, John Samuel.   

Abstract

BACKGROUND: Influenza viral infections are a significant global public health concern due to the morbidity and mortality associated with acute respiratory disease, associated secondary complications and pandemic threat. Currently, the most effective preventative measure is an annual intramuscular (i.m.) injection of a trivalent vaccine. Intramuscular immunization induces strong systemic humoral responses but not mucosal immune responses which are important in the first line of defense against influenza.
OBJECTIVES: A plasmid encoding influenza A/PR/8/34 (H1N1) hemagglutinin (HA; pCI-HA10) was evaluated with respect to the mucosal, cellular and humoral immune responses generated and to its efficacy in protection against a challenge with a lethal dose of influenza. STUDY
DESIGN: BALB/c mice were immunized with pCI-HA10 DNA or liposome-encapsulated pCI-HA10 by either an intranasal (i.n.) or i.m. route. Sera and bronchoalveolar lavage (BAL) fluid were collected at various times and evaluated for HA-specific IgG and IgA antibodies and T cells, isolated from draining lymph nodes and spleens, were analyzed for their proliferative ability. Immunized mice were challenged with a lethal dose (5LD(50)) of influenza and monitored for survival. RESULTS AND
CONCLUSIONS: Intranasal immunization with liposome-encapsulated pCI-HA10 stimulated both IgG and IgA humoral responses and increased IgA titers in BAL fluid, whereas immunization with naked pCI-HA10 had no effect on the antibody response. Intramuscular immunization with both naked and liposome-encapsulated pCI-HA10 elevated serum IgG levels, but had no effect on IgA levels in either the serum or BAL fluid. Both i.n. and i.m. administration of HA vaccine (naked and liposome-encapsulated) elicited T cell proliferative responses. These results suggest that i.n. administration of liposome-encapsulated HA-encoding DNA is effective at eliciting mucosal, cellular and humoral immune responses. Mice immunized i.n. were able to withstand a lethal challenge of influenza virus, confirming that the immune responses mediated by the vaccine were protective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567101     DOI: 10.1016/j.jcv.2004.09.013

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  23 in total

1.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

Review 2.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 3.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

Authors:  Angela Henderson; Katie Propst; Ross Kedl; Steven Dow
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

5.  Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.

Authors:  Hui Wu; Yuanyuan Bao; Xiang Wang; Dongming Zhou; Wenzhe Wu
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

6.  Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Authors:  Dharmendra Raghuwanshi; Vivek Mishra; Dipankar Das; Kamaljit Kaur; Mavanur R Suresh
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

Review 7.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

8.  Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination.

Authors:  Adrienne V Li; James J Moon; Wuhbet Abraham; Heikyung Suh; Jamal Elkhader; Michael A Seidman; Minmin Yen; Eung-Jun Im; Maria H Foley; Dan H Barouch; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2013-09-25       Impact factor: 17.956

9.  CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.

Authors:  Feijun Zhao; Shuangquan Liu; Xiaohong Zhang; Jian Yu; Tiebing Zeng; Weiming Gu; Xunyu Cao; Xi Chen; Yimou Wu
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

10.  Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses.

Authors:  Byoung-Shik Shim; Sung-Moo Park; Ji-Shan Quan; Dhananjay Jere; Hyuk Chu; Man Ki Song; Dong Wook Kim; Yong-Suk Jang; Moon-Sik Yang; Seung Hyun Han; Yong-Ho Park; Chong-Su Cho; Cheol-Heui Yun
Journal:  BMC Immunol       Date:  2010-12-31       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.